The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Edge Therapeutics, Inc. (EDGE)

NEW YORK--()--The Klein Law Firm announces the commencement of an investigation of Edge Therapeutics, Inc. (NASDAQGS: EDGE) concerning possible violations of federal securities laws.

On March 28, 2018, Edge Therapeutics disclosed “that a pre-specified interim analysis on data from the Day 90 visit of the first 210 subjects randomized and treated in the Phase 3 NEWTON 2 study of EG-1962 demonstrated a low probability of achieving a statistically-significant difference compared to the standard of care in the study’s primary endpoint, if the study is fully enrolled.” As a result, the Data Monitoring Committee “recommended that the study be stopped based on its conclusion that the study has a low probability of meeting its primary endpoint.” Based on the DMC recommendation, Edge Therapeutics decided to discontinue the Phase 3 NEWTON 2 study. Upon this news, shares of Edge Therapeutics fell from a close of $15.59 on March 27, 2018, to a close of $1.31 per share on March 28, 2018.

If you suffered a loss in Edge Therapeutics and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kkclasslaw.com/EDGE-Info-Request-Form-297.

Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

The Klein Law Firm
Joseph Klein, Esq., 212-616-4899
Fax: 347-558-9665
www.kleinstocklaw.com

Release Summary

The Klein Law Firm announces the commencement of an investigation of Edge Therapeutics, Inc.

Contacts

The Klein Law Firm
Joseph Klein, Esq., 212-616-4899
Fax: 347-558-9665
www.kleinstocklaw.com